Vaccine Development and Production: Cell Culture Increases

Vaccine Development and Production: Cell Culture Increases ...

The COVID-19 epidemic has spawned a host of scientific advancements, particularly in the production and testing of vaccination technology.

A staggering 10 billion doses of SARS-CoV-2 vaccination have been administered worldwide since December 2020, and while global vaccination equity remains a challenge to overcome, some nations have even begun to experience the SARS-CoV-2 vaccine surplus.

A record number of vaccinations are being sent to clinics through new and rapid production methods, driven at least in part by pandemic management and co-operations.

Since early methods were developed in the 1930s, cell culture has been widely used in the development and testing of new vaccinations. Historically, vaccinations have consisted of a whole or partial pathogen, inactivated for safe administration and grown within biological systems (such as chicken eggs and mammalian cells).

Today, the development of cell-based vaccines continues to be a trendier and rapidly developing.

Cell culture in exploratory vaccine testing

Cell culture techniques are crucial in vaccine development and development. Before they can enter the preclinical stages, vaccine candidates must be proven to be safe and effective.

A high failure rate in preclinical and clinical trials continues to prove a significant obstacle to vaccine manufacturing. Increasing the accuracy and reproducibility of cell culture models remains one of the most important drivers of methodological innovation in vaccine development today.

Adding another dimension to vaccine testing

Cells are grown in flat, two-dimensional (2D) monolayers adhered to the plastic surface of the vessel in which they are grown. Despite its importance in the early stages of exploratory testing, 2D cell culture does not recapitulate the complex tissue structure of in vivo systems and can no longer model the true infection cycle of a pathogen.

Multiple cell types, extracellular matrix components, and some microfluidic systems have helped in vitro''s therapeutic predictions. Unlike 2D experiments, complex multicellular structures can be altered in vitro with greater precision and reproducibility. These 3D cultures can also achieve superior reproducibility and standardization by designing computerized structures.

Dr. Stephanie Willerth, an associate professor of mechanical engineering at the University of Victoria (Canada), believes that 3D bioprinting is a major advantage. Dr. Willerth, in turn, has pursued a career in stem cell bioengineering and 3D cell culture innovation.

As a result, a new tissue model may serve as a benchmark for testing potential vaccines or developing them.

Optimal media for an optimal vaccine

Cell culture media is usually a red or pink liquid in which in vitro cultures are submerged, and this is a mixture of nutrients designed to assist and maximize the growth of cells outside of their natural environment.

The main expenses with 2D cell culture include the media and the labor required to produce cells and resulting structures, according to Willerth. So, making media formulations that last longer and, in turn, reduce the amount of labor required to produce a large amount of cells is crucial.

Cell culture media includes standard amino acids, vitamins, salts, sugars, and other essential nutrients. Animal serum is also sometimes added to provide additional growth factors and hormones which create a tissue environment.

Animal serums are often poorly characterized or standardized if at all. Nearly 1,800 proteins and 4,000 metabolites in a routinely used animal serum have been discovered, resulting in potential variations in in vitro experiments. The removal of animal serum from the vaccine production pipeline has been a key component in accelerating the delivery of therapeutics to market, reducing the number of exploratory tests required for each candidate drug.

The addition of basal synthetic media such as MEM, EMEM, or DMEM with additional lab-derived proteinaceous components andmetabolites improves vaccine production. However, the optimization of cell culture media remains an ongoing process, as researchers continue to strive to mimic the complexity of each true tissue microenvironment.

Replacement, reduction and refinement

Animal products have played an important role in vaccine production for years. However, increasing the public awareness of animal welfare and the scientific hazards associated with animal product contaminants, alternative methods of cell-based production remain a priority for vaccine development.

Many human vaccinations have been successfully and safely in animal cells. Vero cells an ancient cell line from the African green monkey''s kidney epithelium have been widely used in vaccine production, which is proving beneficial in the fight against SARS-CoV-2.

Many experts claim that Vero cells do not provide the biological significance for effective human vaccination development. However, human alternatives are not without their controversies. Johnson & Johnson (Janssen) argued that in 2021, human fetal cells used in the company''s pipeline were lab-derived and did not contain any embryo cells. However, some individuals have decided to refuse this vaccination preparation based on their cell-based production methods.

Going cell free

Messenger ribonucleic acid vaccinations are now a substantial part of the global therapeutic market, promising to continue to be successful in the production of vaccines. The share of the mRNA vaccines is expected to exceed $15.49 billion in the next five years, posing questions about the future of cell culture in mass vaccination production.

In vitro synthesis methods for mRNA vaccination production may now bypass cells entirely, resulting in large quantities of therapeutic grade mRNA within bioreactor systems in a matter of hours. While the potential of this approach has been established for some time, advances in mRNA delivery systems have only recently made cell-free vaccines a possibility. According to some experts, mRNA vaccination technology may sooner replace cell-based production methods.

Dr. Namit Chaudhary is a graduate student at Carnegie Mellon University (Pittsburgh) who is working on the development of lipoprotein nanoparticles (LNPs) to provide therapeutics that are flexible and safe for infectious diseases such as HIV, influenza, RSV, CMV, and others. He has already identified candidates for the flu vaccine. Both Moderna and Sanofi have already identified candidates for the flu vaccine in clinical trials. However, Depending on the results, we may have an

RNA vaccines can provide substantial relative costs and infrastructure requirements. One of the key challenges limiting the widespread use of RNA vaccines is their ultra-cold storage requirements, according to Chaudhary. Thermostable vaccines [like those produced using cell-based methods] that are stable at room temperature for extended periods of time will enable vaccination distribution in low-income countries.

Cell-based vaccine production is here to stay

While all COVID-19 vaccinations have shown success in clinical trials and all have been tested using cell culture techniques, there is still room for improvement when it comes to cell-based vaccine production.

The availability of LNP technology for mRNA vaccine production might offer new, cell-free synthesis options, but cells remain necessary for post-production testing. I believe there is still room in the market for all technologies, according to Chaudhary. However, cell culture and animal models are still required to verify vaccine candidates'' efficacy and immune response.

High costs associated with lab infrastructure, training, and reagents might perpetuate the bioeconomic benefits of already wealthy nations. Further steps are required to ensure that technological advancements in vaccine production can lead to global vaccination equity and public health.

You may also like: